title: NICE guidance on pembrolizumab for advanced melanoma.
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK. Electronic address: ian.watson@nice.org.uk.
authors.forename: Ian
authors.initials: I
authors.lastname: Watson
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Pilar Pinilla
authors.initials: PP
authors.lastname: Dominguez
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Eleanor
authors.initials: E
authors.lastname: Donegan
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Zoe
authors.initials: Z
authors.lastname: Charles
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Janet
authors.initials: J
authors.lastname: Robertson
authors.affiliation: Department of Diagnostic Radiology, St George's Hospital, London, UK.
authors.forename: E Jane
authors.initials: EJ
authors.lastname: Adam
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D006113:United Kingdom
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C582435:pembrolizumab